Specialty Pharmaceuticals and Patient Privacy

Specialty Pharmaceuticals and Patient Privacy

In the specialty pharmaceutical industry, patient privacy is crucial. Privacy can be a challenge for companies looking to gather and consolidate patient information from various sources. The de-identification of that information is critical to unlocking the ability to use this data to make smarter business decisions and enhance drug development.

De-identifying data can provide pharmaceutical companies with a variety of benefits, including:

  • The ability to assess the value and effectiveness of a drug
  • Provide improved support for patients
  • Enhance research and contribute to new breakthroughs

Read our white paper to learn how de-identifying data can help biopharmaceutical companies tap into the broad base of evidence required to support and grow business, while maintaining patient privacy.

Here are key highlights from April 2022 detailing global news and regulatory updates. US & Canada Canada’s privacy commissioner urges government to update federal…
Here are key highlights from March 2022 detailing global news and regulatory updates. US & Canada Canadian Bar Association identifies ways to improve the…
Previous
Next

Join the next 5 Safes Data Privacy webinar

This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.